–    Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing CARLSBAD, Calif. , Oct. 3, 2024 /PRNewswire/ — Ionis Pharmaceuticals , Inc.  (Nasdaq: IONS) announced today that it will

Zilganersen is the first investigational medicine in clinical development for adults and children living with Alexander disease, an ultra-rare neurological condition CARLSBAD, Calif. , Oct. 1, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc.  (Nasdaq: IONS) announced today that the U.S.

CARLSBAD, Calif. , Sept. 9, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The shares of common stock are being sold at a public offering price of $43.50 per share.

CARLSBAD, Calif. , Sept. 9, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares

WAINUA TM  U.S. launch progressing well; approved in Canada ; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif.